Crucell announces acquisition of SBL Vaccin AB
Dutch biotech company, Crucell, has completed its takeover of SBL Vaccin AB. The €39.4 million deal is set to strengthen Crucell's sales organization in Scandanavia. In 2005, SBL generated sales of around €25.2 million with a cash flow of €0.6 million.
Through Q3 of 2006, the company made €17.6 million in revenues, with €0.5 million in EBIT and €2.7 million in cash flow. However, the main interest for Crucell is Dukoral - an oral vaccine against cholera and ETEC (traveller's diarrhoea), which will further expand and strengthen Crucell's portfolio of travel vaccines. The vaccine is registered in over 50 countries, and sales have increased by over 60% since 2004, exceeding €14 million in 2005.
www.crucell.com
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.